Patent protection is expiring for multibillion-dollar medicines later this decade, forcing drugmakers to find new products and markets. From M&A strategies to emerging therapeutic areas, companies are reshaping their commercial approaches to sustain growth. INCLUDED IN THIS TRENDLINE Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. Trump revives pharma tariffs with 100% charges, but leaves loopholes Novo, Hims reach deal to sell GLP-1 drugs together
